- Home
- HSCS
as 10-29-2025 9:38am EST
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SOUTHLAKE |
| Market Cap: | 9.9M | IPO Year: | 2022 |
| Target Price: | $10.50 | AVG Volume (30 days): | 25.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.52 - $6.47 | Next Earning Date: | 12-15-2025 |
| Revenue: | $6,250 | Revenue Growth: | -66.40% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Heart Test Laboratories Inc. News
HSCS Breaking Stock News: Dive into HSCS Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
HeartSciences Inc. (HSCS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GlobeNewswire
2 months ago
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
GlobeNewswire
3 months ago
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
TipRanks
5 months ago
HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm
GlobeNewswire
5 months ago
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
GlobeNewswire
5 months ago
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
TipRanks
5 months ago
HeartSciences signs first MyoVista Insights platform customer
GlobeNewswire
5 months ago
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
Compare HSCS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HSCS Heart Test Laboratories Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.